

Environmental Risk Assessment for Pharmaceuticals

Pharmaron offers a complete Environmental Risk Assessment (ERA) service to our pharmaceutical clients. Together with our partners, we conduct all studies required for Phase I, IIA and IIB ERAs for registration in the US, Europe and Japan. We provide regulatory consultancy and program management, if required. Our environmental fate studies can be closely integrated with the radiosynthesis and radiolabelling of test materials with ¹⁴C and/or ³H.

Capabilities

- Custom Radiosynthesis of ¹⁴C and ³H Compounds
- GLP Certificates of Analysis
- Environmental Fate
- Physical Chemistry
- Biodegradation
- Aquatic Ecotoxicology
- Terrestrial Ecotoxicology
- Program Management
- Tier Summaries
- Regulatory Consultancy

Services

Environmental Fate

- OECD 106 Adsorption/Desorption
- OECD 307 Aerobic and Anaerobic Transformation in Soil
- OECD 308 Aerobic and Anaerobic Transformation in Aquatic Sediment Systems
- OECD 309 Aerobic Mineralisation

Physical Chemistry

- OECD 101 UV-Visible Absorption Spectrum
- OECD 102 Melting Point/Range
- OECD 104 Vapour Pressure
- OECD 105 Water Solubility
- OECD 107 Partition Coefficient (N-Octanol/Water) Shake Flask Method
- OECD 112 Dissociation in Water
- OECD 123 Partition Coefficient (1-Octanol/Water) Slow-stirring Method

Biodegradation

- OECD 209 Activated Sludge, Respiration Inhibition Test
- OECD 301 Ready Biodegradation

Aquatic Ecotoxicology

- OECD 201 Algal Growth Inhibition
- OECD 210 Fish Early Life Stage
- OECD 211 Daphnia Reproduction
- OECD 218 Chironomid Toxicity Test using Spiked Sediment
- OECD 219 Chironomid Toxicity Test using Spiked Water
- OECD 305 Fish Bioconcentration

Terrestrial Ecotoxicology

- OECD 207 Acute Earthworm
- OECD 208 Terrestrial Plant Growth
- OECD 232 Collembolan Reproduction Test in Soil





Laboratory Services



Chemistry, Manufacturing and Control



Clinical Development



Pharmaron is a premier R&D service provider for the life sciences industry that offers a broad spectrum of research, development and manufacturing service capabilities throughout the entire drug discovery, preclinical and clinical development process across multiple therapeutic modalities, including small molecules, biologics and CGT products.